|By Marketwired .||
|April 29, 2014 07:00 PM EDT||
SAN DIEGO, CA -- (Marketwired) -- 04/29/14 -- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference to be held at the Encore at Wynn hotel in Las Vegas, Nevada on Tuesday, May 13, 2014.
Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present that day at 6:00 p.m. Eastern time (3:00 p.m. Pacific time) with a question and answer session scheduled immediately following the presentation. During the presentation, the company will discuss business and financial developments and trends. The company's statements may contain or constitute material information that has not been previously disclosed.
A live webcast and audio archive of the presentation will be available via the Investor Relations section of the company's Web site at www.quidel.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the company's Web site for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and wellbeing of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the QuickVue®, D3® Direct Detection and Thyretain® leading brand names, as well as under the new Sofia®, AmpliVue® and Lyra brands, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit quidel.com.
Chief Financial Officer
Media and Investors Contact:
Jul. 3, 2015 08:00 PM EDT Reads: 691
Jul. 3, 2015 07:15 PM EDT Reads: 600
Jul. 3, 2015 07:00 PM EDT Reads: 731
Jul. 3, 2015 07:00 PM EDT Reads: 876
Jul. 3, 2015 06:30 PM EDT Reads: 1,264
Jul. 3, 2015 05:30 PM EDT Reads: 570
Jul. 3, 2015 05:00 PM EDT Reads: 940
Jul. 3, 2015 04:45 PM EDT Reads: 860
Jul. 3, 2015 04:15 PM EDT Reads: 722
Jul. 3, 2015 02:45 PM EDT Reads: 920
Jul. 3, 2015 02:45 PM EDT Reads: 833
Jul. 3, 2015 02:00 PM EDT Reads: 2,183
Jul. 3, 2015 02:00 PM EDT Reads: 2,145
Jul. 3, 2015 01:30 PM EDT Reads: 1,168
Jul. 3, 2015 12:30 PM EDT Reads: 1,404